Securities Fraud Class Action Filed Against Picard Medical, Inc.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy PMI?
Source: Businesswire
- Stock Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, closing at $3.99 from $13.20 per share, indicating a severe loss of investor confidence and significant financial repercussions for shareholders.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, with insiders using offshore accounts to facilitate share dumping, misleading investors about the company's true financial health.
- Investor Rights: Affected investors have until April 3, 2026, to file a lead plaintiff motion to seek claims under federal securities laws, highlighting the legal framework aimed at protecting investor interests in the face of corporate misconduct.
- Legal Action Context: This lawsuit raises serious questions about the company's transparency and integrity, potentially leading to stricter regulatory scrutiny that could impact Picard's future financing capabilities and market reputation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PMI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PMI
About PMI
Picard Medical, Inc. is a holding company that owns a 100% interest in SynCardia Systems, LLC (SynCardia). SynCardia is a medical technology company that manufactures and sells the only United States Food and Drug Administration (FDA) and Health Canada-approved implantable total artificial heart (SynCardia TAH). The SynCardia TAH is a biventricular replacement device that consists of the SynCardia TAH implant, an external pneumatic driver that delivers precisely calibrated pulses of air to drive the implant, and drivelines that connect the driver to the implant. The SynCardia TAH implant is a system that consists of two independent artificial ventricles which are powered by an external pneumatic driver. Each artificial ventricle is made of a semi-rigid polyurethane housing and a rigid polyurethane base, with a four-layer flexible polyurethane diaphragm separating the blood chamber from the air chamber.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Securities Fraud Class Action Filed Against Picard Medical, Inc.
- Stock Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, closing at $3.99 from $13.20 per share, indicating a severe loss of investor confidence and significant financial repercussions for shareholders.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, with insiders using offshore accounts to facilitate share dumping, misleading investors about the company's true financial health.
- Investor Rights: Affected investors have until April 3, 2026, to file a lead plaintiff motion to seek claims under federal securities laws, highlighting the legal framework aimed at protecting investor interests in the face of corporate misconduct.
- Legal Action Context: This lawsuit raises serious questions about the company's transparency and integrity, potentially leading to stricter regulatory scrutiny that could impact Picard's future financing capabilities and market reputation.
See More
Class Action Filed Against Picard Medical Following Stock Collapse
- Class Action Initiation: Scott+Scott Attorneys at Law has filed a class action lawsuit against Picard Medical and its executives, alleging manipulation of stock prices through false advertising between September and October 2025, resulting in significant investor losses.
- False Advertising Allegations: The lawsuit claims that the defendants failed to disclose material adverse facts about the company's operations and engaged in fraudulent social media promotions that artificially inflated Picard Medical's stock price, constituting a pump-and-dump scheme.
- Investor Losses: Affected investors who purchased Picard Medical securities between September 2 and October 31, 2025, are encouraged to contact attorneys for compensation, highlighting the severe impact of this incident on investor confidence.
- Legal Timeline: The lead plaintiff deadline for this class action is April 13, 2026, requiring investors to file with the court by this date to ensure their rights are protected in the lawsuit.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American: PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, which resulted in significant losses for investors once the truth was revealed, highlighting serious compliance risks within the company.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights and participate in the litigation.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to take action may remain absent class members, potentially forfeiting their claims.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statement Allegations: The complaint alleges that Picard Medical made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in investor losses when the truth was revealed, indicating insider selling at artificially inflated prices.
- Legal Representation Information: The Schall Law Firm specializes in securities class action lawsuits and offers free consultations to affected investors, emphasizing their commitment to protecting shareholder rights and pursuing compensation for losses incurred.
- Uncertified Class Action: The class action has not yet been certified, meaning investors are not represented by an attorney unless they take action, highlighting the importance of participation in the lawsuit to avoid being an absent class member.
See More
Class Action Lawsuit Announced for Picard Medical Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit for investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, indicating significant legal risks that may impact the company's stock performance.
- Basis for Lawsuit: The lawsuit alleges that Picard Medical failed to disclose critical adverse facts regarding its business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media, which could lead to investor losses.
- Investor Rights Protection: Investors joining the lawsuit are not required to pay any upfront fees and can seek compensation through contingency arrangements, highlighting the law firm's commitment to protecting investor rights and potentially attracting more affected investors.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Picard Medical Faces Class Action Over Fraud Allegations
- Fraud Allegations: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly being involved in a fraudulent stock promotion scheme, impacting securities transactions between September 2 and October 31, 2025, which may lead to significant investor losses.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from $13.30 to $3.99, and has since continued to decline to approximately $2.00, raising serious concerns about the company's financial health and investor confidence.
- Insider Trading Investigation: The complaint alleges that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping, failing to disclose false rumors and artificial trading activities to investors, exacerbating stock price volatility.
- Legal Action Notification: Investors are eligible to file papers by April 3, 2026, to serve as lead plaintiffs in the class action, representing other shareholders, highlighting the importance of corporate governance and the protection of shareholder rights.
See More
Securities Fraud Class Action Filed Against Picard Medical, Inc.
- Stock Crash: On October 23, 2025, Picard Medical's stock plummeted approximately 70% during after-hours trading, closing at $3.99 from $13.20 per share, indicating a severe loss of investor confidence and significant financial repercussions for shareholders.
- Fraud Allegations: The lawsuit alleges that throughout the class period from September 2 to October 31, 2025, Picard failed to disclose that its stock was subject to a fraudulent social media promotion scheme, with insiders using offshore accounts to facilitate share dumping, misleading investors about the company's true financial health.
- Investor Rights: Affected investors have until April 3, 2026, to file a lead plaintiff motion to seek claims under federal securities laws, highlighting the legal framework aimed at protecting investor interests in the face of corporate misconduct.
- Legal Action Context: This lawsuit raises serious questions about the company's transparency and integrity, potentially leading to stricter regulatory scrutiny that could impact Picard's future financing capabilities and market reputation.
See More
Class Action Filed Against Picard Medical Following Stock Collapse
- Class Action Initiation: Scott+Scott Attorneys at Law has filed a class action lawsuit against Picard Medical and its executives, alleging manipulation of stock prices through false advertising between September and October 2025, resulting in significant investor losses.
- False Advertising Allegations: The lawsuit claims that the defendants failed to disclose material adverse facts about the company's operations and engaged in fraudulent social media promotions that artificially inflated Picard Medical's stock price, constituting a pump-and-dump scheme.
- Investor Losses: Affected investors who purchased Picard Medical securities between September 2 and October 31, 2025, are encouraged to contact attorneys for compensation, highlighting the severe impact of this incident on investor confidence.
- Legal Timeline: The lead plaintiff deadline for this class action is April 13, 2026, requiring investors to file with the court by this date to ensure their rights are protected in the lawsuit.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American: PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statements Allegation: The complaint alleges that Picard made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, which resulted in significant losses for investors once the truth was revealed, highlighting serious compliance risks within the company.
- Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover their losses, with the Schall Law Firm specializing in securities class actions and offering free consultations to help affected shareholders understand their rights and participate in the litigation.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, and those who choose not to take action may remain absent class members, potentially forfeiting their claims.
See More
Class Action Lawsuit Reminder Against Picard Medical, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Picard Medical, Inc. (NYSE American:PMI) for violations of securities laws during the period from September 2, 2025, to October 31, 2025, urging affected investors to contact the firm before April 3, 2026, to participate in the lawsuit.
- False Statement Allegations: The complaint alleges that Picard Medical made false and misleading statements, engaging in a manipulation scheme to fraudulently inflate its stock price, resulting in investor losses when the truth was revealed, indicating insider selling at artificially inflated prices.
- Legal Representation Information: The Schall Law Firm specializes in securities class action lawsuits and offers free consultations to affected investors, emphasizing their commitment to protecting shareholder rights and pursuing compensation for losses incurred.
- Uncertified Class Action: The class action has not yet been certified, meaning investors are not represented by an attorney unless they take action, highlighting the importance of participation in the lawsuit to avoid being an absent class member.
See More
Class Action Lawsuit Announced for Picard Medical Securities
- Class Action Initiation: Rosen Law Firm has announced a class action lawsuit for investors who purchased Picard Medical (NYSE American: PMI) securities between September 2 and October 31, 2025, indicating significant legal risks that may impact the company's stock performance.
- Basis for Lawsuit: The lawsuit alleges that Picard Medical failed to disclose critical adverse facts regarding its business and securities trading during the class period, including a fraudulent stock promotion scheme involving social media, which could lead to investor losses.
- Investor Rights Protection: Investors joining the lawsuit are not required to pay any upfront fees and can seek compensation through contingency arrangements, highlighting the law firm's commitment to protecting investor rights and potentially attracting more affected investors.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Picard Medical Faces Class Action Over Fraud Allegations
- Fraud Allegations: Robbins LLP has alerted investors that Picard Medical (PMI) is facing a class action lawsuit for allegedly being involved in a fraudulent stock promotion scheme, impacting securities transactions between September 2 and October 31, 2025, which may lead to significant investor losses.
- Stock Price Crash: On October 24, 2025, Picard Medical's stock price plummeted by 70%, dropping from $13.30 to $3.99, and has since continued to decline to approximately $2.00, raising serious concerns about the company's financial health and investor confidence.
- Insider Trading Investigation: The complaint alleges that insiders and affiliates used offshore or nominee accounts to facilitate coordinated share dumping, failing to disclose false rumors and artificial trading activities to investors, exacerbating stock price volatility.
- Legal Action Notification: Investors are eligible to file papers by April 3, 2026, to serve as lead plaintiffs in the class action, representing other shareholders, highlighting the importance of corporate governance and the protection of shareholder rights.
See More
